PMDD vs. PMS: How to Tell the Difference and What Actually Helps

For three weeks of the month you're yourself. Then, like clockwork, about a week before your period, something shifts. You snap at your kids. You cry in the car. A small comment at work feels unbearable. You feel hopeless in a way that makes no sense, and then your period starts and within a day or two it lifts.

If that sounds familiar, it may be more than PMS. It may be premenstrual dysphoric disorder, or PMDD.

The difference in one sentence

PMS is uncomfortable. PMDD is disabling.

Most women notice some premenstrual symptoms: bloating, breast tenderness, irritability, food cravings. That's PMS. PMDD is a separate, recognized condition in the DSM-5, where the mood symptoms are severe enough to disrupt work, relationships, or daily life.

That prevalence comes from a 2024 Oxford meta-analysis of 44 studies and more than 50,000 women. The researchers think 1.6% is likely an underestimate, because the strict diagnostic rules mean many women never get formally diagnosed.

The symptoms

PMDD requires at least five symptoms in the week before your period, improving within a few days after it starts and minimal the week after. At least one has to be a core mood symptom:

• Marked mood swings, or sudden sensitivity to rejection
• Marked irritability or anger, or more conflict with people
• Depressed mood or hopelessness
• Anxiety or tension, feeling keyed up or on edge

Others can include:

• Losing interest in usual activities
• Trouble concentrating
• Fatigue and low energy
• Changes in appetite or strong cravings
• Sleeping too much or too little
• Feeling overwhelmed or out of control
• Physical symptoms like breast tenderness, bloating, or joint and muscle pain

How it's diagnosed: track it

PMDD can't be diagnosed from one appointment or a blood test. It's diagnosed by tracking your symptoms every day for at least two menstrual cycles.

The standard tool is the Daily Record of Severity of Problems (DRSP), a checklist where you rate each symptom daily. The International Association for Premenstrual Disorders recommends filling it in on the day, not reconstructing it later, because memory is unreliable when you're exhausted or distressed.

Tracking does two things. It confirms the timing, and it separates PMDD from premenstrual exacerbation, where an existing condition like depression, anxiety, or ADHD gets worse before your period but is present all month. That distinction matters, because the treatment is different. For how this overlaps with perimenopause, see Perimenopause Anxiety vs. Generalized Anxiety Disorder.

Why it happens: it's not your hormone levels

This is the part most women are never told. Women with PMDD usually have normal estrogen and progesterone levels. The problem is how the brain responds to normal changes in those hormones.

The key evidence comes from the National Institute of Mental Health. In a 1998 study published in the New England Journal of Medicine, researchers shut down the menstrual cycle in women with PMS using a medication. Their symptoms improved. When the researchers added estrogen or progesterone back, symptoms returned. In women without PMS, the same hormones caused no mood change at all.

In 2017, the same group found a likely reason at the cellular level. Cells from women with PMDD showed different activity in a set of genes, called the ESC/E(Z) complex, that controls how cells respond to sex hormones and stress.

So testing your hormone levels won't diagnose PMDD, and "balancing" levels that are already normal isn't the answer. The goal is to steady the brain's response to the monthly shifts. A lot of this runs through progesterone's calming breakdown product, allopregnanolone, which acts on the same brain receptors as anti-anxiety medications. For more, see What Does Progesterone Do?

What helps

SSRIs

SSRIs are the best-studied treatment. A 2024 Cochrane review of 34 trials and more than 4,500 women found they probably reduce premenstrual symptoms.

Unlike in depression, SSRIs often work within days for PMDD, so some women take them only in the two weeks before their period. The Cochrane review found daily dosing worked somewhat better than luteal-phase-only dosing, though both helped. Side effects such as nausea and low energy were more common than with placebo.

Hormonal options

• Drospirenone-containing birth control pills. A pill containing drospirenone and ethinyl estradiol (Yaz) was approved by the FDA in 2006 for PMDD in women who also want contraception.
• Ovarian suppression, using medications that temporarily shut down the cycle, is used for severe PMDD that doesn't respond to other treatment. It's usually given with add-back hormones to protect bone.

Calcium

Calcium is one of the few supplements with a solid trial behind it. In a 1998 randomized trial of 466 women with PMS, 1,200 mg a day of elemental calcium, as calcium carbonate, reduced total symptoms by 48% by the third cycle, compared with 30% on placebo. That trial was in PMS rather than diagnosed PMDD, but it's low-risk and worth trying. Calcium is available through my Fullscript dispensary. Check with your clinician if you have a history of kidney stones.

Daily habits that help the brain's response

• Cognitive behavioral therapy can reduce how much premenstrual symptoms disrupt your life, and gives you tools for the hard week.
• Regular exercise through the whole month.
• Steady blood sugar, with protein at meals, since cravings and crashes amplify mood swings.
• Less alcohol and caffeine in the premenstrual week.
• Protecting sleep, which is often the first thing to slip.

A word about safety

PMDD is linked to a real increase in suicidal thoughts. A 2021 meta-analysis in the Journal of Women's Health found women with PMDD had about four times the odds of suicidal thoughts and about seven times the odds of a suicide attempt compared with women without it.

If you have thoughts of harming yourself, during your premenstrual week or any time, call or text 988 in the US to reach the Suicide & Crisis Lifeline, or go to the nearest emergency room. These thoughts are a symptom, and they are treatable.

What you can do now

1. Start tracking daily with the DRSP or a similar symptom diary. Two cycles of data is what gets you a diagnosis.
2. Note whether symptoms clear within a few days of your period. If they don't, ask about premenstrual exacerbation of another condition.
3. Bring your tracking to your appointment, and ask about SSRIs, hormonal options, and therapy.
4. Try calcium, exercise, and steady meals alongside treatment.

PMDD isn't a character flaw or a lack of coping. It's a recognized condition with a biological cause, and it responds to treatment.

References

1. Reilly TJ, et al. The prevalence of premenstrual dysphoric disorder: systematic review and meta-analysis. J Affect Disord. 2024. Summary from the University of Oxford. View source
2. International Association for Premenstrual Disorders. What is the DRSP and why is it important for PMDD diagnosis and research? View source
3. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209-216. Summary in Relias Media. View source
4. National Institutes of Health. Sex hormone-sensitive gene complex linked to premenstrual mood disorder (Dubey N, et al. Mol Psychiatry). January 3, 2017. View source
5. Jespersen C, Lauritsen MP, Frokjaer VG, Schroll JB. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database Syst Rev. 2024. View source
6. FDA OKs new indication for Schering AG's YAZ (PMDD). The Pharma Letter. 2006. View source
7. Thys-Jacobs S, Starkey P, Bernstein D, Tian J; Premenstrual Syndrome Study Group. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol. 1998. View source
8. Prasad D, Wollenhaupt-Aguiar B, Kidd KN, de Azevedo Cardoso T, Frey BN. Suicidal risk in women with premenstrual syndrome and premenstrual dysphoric disorder: a systematic review and meta-analysis. J Womens Health. 2021;30(12):1693-1707. View source